New approaches for human epidermal growth factor receptor 2-low and human epidermal growth factor receptor 2-overexpressing metastatic breast cancer

被引：0

作者：

Britten, Karissa ^{[1
]}

McAndrew, Nicholas ^{[1
]}

机构：

[1] Univ Calif Los Angeles, Div Hematol Oncol, Los Angeles, CA USA

来源：

CURRENT OPINION IN OBSTETRICS & GYNECOLOGY | 2024年 / 36卷 / 01期

关键词：

human epidermal growth factor receptor 2 testing; human epidermal growth factor receptor 2+breast cancer; human epidermal growth factor receptor 2-low breast cancer; human epidermal growth factor receptor 2-targeted therapy; POLYMERASE CHAIN-REACTION; ANTIBODY-DRUG CONJUGATE; IN-SITU HYBRIDIZATION; TRASTUZUMAB DERUXTECAN; MONOCLONAL-ANTIBODY; HER2; IMMUNOHISTOCHEMISTRY; DS-8201A; CHEMOTHERAPY; EXPRESSION;

D O I：

10.1097/GCO.0000000000000930

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Purpose of review In recent years, there has been a flurry of activity in the human epidermal growth factor receptor 2 (HER2)positive metastatic breast cancer space. New, powerful drugs like trastuzumab deruxtecan have challenged our fundamental definition of what HER2 expression means as a predictive biomarker. Recent findings Recent approvals of multiple agents in the second line-metastatic setting have given patients access to a variety of new agents, but also raise questions with regard to optimal sequencing. Summary This review will explore current issues with HER2 testing, recently approved drugs in the HER2+ and HER2 low spaces, as well as novel agents/combinations on the horizon.

引用

页码：34 / 39

页数：6

共 42 条

[21] Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Central Nervous System Metastases [J].

Leyland-Jones, Brian .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (31) :5278-5286

[22] Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial [J].

Lin, Nancy U. ;

Borges, Virginia ;

Anders, Carey ;

Murthy, Rashmi K. ;

Paplomata, Elisavet ;

Hamilton, Erika ;

Hurvitz, Sara ;

Loi, Sherene ;

Okines, Alicia ;

Abramson, Vandana ;

Bedard, Philippe L. ;

Oliveira, Mafalda ;

Mueller, Volkmar ;

Zelnak, Amelia ;

DiGiovanna, Michael P. ;

Bachelot, Thomas ;

Chien, A. Jo ;

O'Regan, Ruth ;

Wardley, Andrew ;

Conlin, Alison ;

Cameron, David ;

Carey, Lisa ;

Curigliano, Giuseppe ;

Gelmon, Karen ;

Loibl, Sibylle ;

Mayor, JoAl ;

McGoldrick, Suzanne ;

An, Xuebei ;

Winer, Eric P. .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (23) :2610-+

[23] Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond [J].

Marchio, Caterina ;

Annaratone, Laura ;

Marques, Ana ;

Casorzo, Laura ;

Berrino, Enrico ;

Sapino, Anna .

SEMINARS IN CANCER BIOLOGY, 2021, 72 :123-135

[24] Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer [J].

Modi, Shanu ;

Jacot, William ;

Yamashita, Toshinari ;

Sohn, Joohyuk ;

Vidal, Maria ;

Tokunaga, Eriko ;

Tsurutani, Junji ;

Ueno, Naoto T. ;

Prat, Aleix ;

Chae, Yee Soo ;

Lee, Keun Seok ;

Niikura, Naoki ;

Park, Yeon Hee ;

Xu, Binghe ;

Wang, Xiaojia ;

Gil-Gil, Miguel ;

Li, Wei ;

Pierga, Jean-Yves ;

Im, Seock-Ah ;

Moore, Halle C. F. ;

Rugo, Hope S. ;

Yerushalmi, Rinat ;

Zagouri, Flora ;

Gombos, Andrea ;

Kim, Sung-Bae ;

Liu, Qiang ;

Luo, Ting ;

Saura, Cristina ;

Schmid, Peter ;

Sun, Tao ;

Gambhire, Dhiraj ;

Yung, Lotus ;

Wang, Yibin ;

Singh, Jasmeet ;

Vitazka, Patrik ;

Meinhardt, Gerold ;

Harbeck, Nadia ;

Cameron, David A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (01) :9-20

[25] Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer [J].

Modi, Shanu ;

Saura, Cristina ;

Yamashita, Toshinari ;

Park, Yeon Hee ;

Kim, Sung-Bae ;

Tamura, Kenji ;

Andre, Fabrice ;

Iwata, Hiroji ;

Ito, Yoshinori ;

Tsurutani, Junji ;

Sohn, Joohyuk ;

Denduluri, Neelima ;

Perrin, Christophe ;

Aogi, Kenjiro ;

Tokunaga, Eriko ;

Im, Seock-Ah ;

Lee, Keun Seok ;

Hurvitz, Sara A. ;

Cortes, Javier ;

Lee, Caleb ;

Chen, Shuquan ;

Zhang, Lin ;

Shahidi, Javad ;

Yver, Antoine ;

Krop, Ian .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (07) :610-621

[26] Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer [J].

Moutafi, Myrto ;

Robbins, Charles J. ;

Yaghoobi, Vesal ;

Fernandez, Aileen, I ;

Martinez-Morilla, Sandra ;

Xirou, Vasiliki ;

Bai, Yalai ;

Song, Yan ;

Gaule, Patricia ;

Krueger, Joseph ;

Bloom, Kenneth ;

Hill, Salisha ;

Liebler, Daniel C. ;

Fulton, Regan ;

Rimm, David L. .

LABORATORY INVESTIGATION, 2022, 102 (10) :1101-1108

[27] Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer [J].

Murthy, R. K. ;

Loi, S. ;

Okines, A. ;

Paplomata, E. ;

Hamilton, E. ;

Hurvitz, S. A. ;

Lin, N. U. ;

Borges, V. ;

Abramson, V. ;

Anders, C. ;

Bedard, P. L. ;

Oliveira, M. ;

Jakobsen, E. ;

Bachelot, T. ;

Shachar, S. S. ;

Mueller, V. ;

Braga, S. ;

Duhoux, F. P. ;

Greil, R. ;

Cameron, D. ;

Carey, L. A. ;

Curigliano, G. ;

Gelmon, K. ;

Hortobagyi, G. ;

Krop, I. ;

Loibl, S. ;

Pegram, M. ;

Slamon, D. ;

Palanca-Wessels, M. C. ;

Walker, L. ;

Feng, W. ;

Winer, E. P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (07) :597-609

[28] The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy [J].

Nakada, Takashi ;

Sugihara, Kiyoshi ;

Jikoh, Takahiro ;

Abe, Yuki ;

Agatsuma, Toshinori .

CHEMICAL & PHARMACEUTICAL BULLETIN, 2019, 67 (03) :173-185

[29] DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1 [J].

Ogitani, Yusuke ;

Aida, Tetsuo ;

Hagihara, Katsunobu ;

Yamaguchi, Junko ;

Ishii, Chiaki ;

Harada, Naoya ;

Soma, Masako ;

Okamoto, Hiromi ;

Oitate, Masataka ;

Arakawa, Shingo ;

Hirai, Takehiro ;

Atsumi, Ryo ;

Nakada, Takashi ;

Hayakawa, Ichiro ;

Abe, Yuki ;

Agatsuma, Toshinori .

CLINICAL CANCER RESEARCH, 2016, 22 (20) :5097-5108

[30] Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity [J].

Ogitani, Yusuke ;

Hagihara, Katsunobu ;

Oitate, Masataka ;

Naito, Hiroyuki ;

Agatsuma, Toshinori .

CANCER SCIENCE, 2016, 107 (07) :1039-1046

← 1 2 3 4 5 →